- Home
- MAIA vs RAND Comparison
MAIA vs RAND Comparison
Compare MAIA & RAND Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MAIA
- RAND
- Stock Information
- Founded
- MAIA 2018
- RAND 1969
- Country
- MAIA United States
- RAND United States
- Employees
- MAIA N/A
- RAND N/A
- Industry
- MAIA Biotechnology: Pharmaceutical Preparations
- RAND Finance: Consumer Services
- Sector
- MAIA Health Care
- RAND Finance
- Exchange
- MAIA Nasdaq
- RAND Nasdaq
- Market Cap
- MAIA 56.3M
- RAND 54.4M
- IPO Year
- MAIA 2022
- RAND N/A
- Fundamental
- Price
- MAIA $1.59
- RAND $14.82
- Analyst Decision
- MAIA
- RAND
- Analyst Count
- MAIA 0
- RAND 0
- Target Price
- MAIA N/A
- RAND N/A
- AVG Volume (30 Days)
- MAIA 375.5K
- RAND 5.8K
- Earning Date
- MAIA 08-11-2025
- RAND 11-05-2025
- Dividend Yield
- MAIA N/A
- RAND 11.10%
- EPS Growth
- MAIA N/A
- RAND N/A
- EPS
- MAIA N/A
- RAND N/A
- Revenue
- MAIA N/A
- RAND $7,966,118.00
- Revenue This Year
- MAIA N/A
- RAND N/A
- Revenue Next Year
- MAIA N/A
- RAND N/A
- P/E Ratio
- MAIA N/A
- RAND N/A
- Revenue Growth
- MAIA N/A
- RAND 1.16
- 52 Week Low
- MAIA $1.40
- RAND $13.82
- 52 Week High
- MAIA $3.74
- RAND $31.89
- Technical
- Relative Strength Index (RSI)
- MAIA 50.99
- RAND 37.13
- Support Level
- MAIA $1.46
- RAND $14.54
- Resistance Level
- MAIA $1.65
- RAND $16.73
- Average True Range (ATR)
- MAIA 0.09
- RAND 0.67
- MACD
- MAIA 0.01
- RAND -0.06
- Stochastic Oscillator
- MAIA 43.10
- RAND 12.73
About MAIA MAIA Biotechnology Inc.
MAIA Biotechnology Inc is a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer. THIO (6-thio-dG or 6-thio-2 '-deoxyguanosine), its lead asset, is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. Patients with advanced NSCLC will be treated first with THIO followed a few days later by the immune checkpoint inhibitor Libtayo (cemiplimab), manufactured and commercialized by Regeneron.
About RAND Rand Capital Corporation
Rand Capital Corp is a closed-end, externally managed, non-diversified investment company. The company's investment objective is to generate current income and, when possible, complement its current income with capital appreciation by focusing its debt and related equity investments in privately-held, lower middle market companies with committed and experienced managements in a broad variety of industries. It predominantly invests in higher-yielding debt instruments.